• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Infectious Disease

Near-point-of-care molecular test accurately detects pulmonary tuberculosis

byHannan Minhas, MScandThomas Su
May 4, 2026
in Infectious Disease
Reading Time: 3 mins read
Shorter moxifloxacin-containing regimens ineffective for treating TB [REMoxTB trial]
Share on FacebookShare on TwitterShare on LinkedIn

1. In patients with presumptive pulmonary tuberculosis, the MiniDock MTB molecular test using sputum and tongue swabs showed diagnostic accuracy consistent with World Health Organization targets for near-point-of-care tuberculosis testing. 

2. Sputum-swab MiniDock MTB had sensitivity similar to polymerase-chain-reaction assays, and both sputum- and tongue-swab testing were more sensitive than sputum-smear microscopy, with good usability and no test-related adverse events. 

Evidence Rating Level: 2 (Good)

Study Rundown: Tuberculosis remains a leading infectious cause of death worldwide, but access to rapid molecular testing is still limited in many high-burden settings. Sputum-based diagnostics can also be difficult to deploy in peripheral clinics and may be limited by patients’ inability to produce sputum. MiniDock MTB is a portable, low-cost molecular platform designed to test both sputum swabs and tongue swabs near the point of care. Prior work with prototype versions suggested promising diagnostic performance, but the accuracy and usability of the finalized clinical-use version were not yet clear. Hence, this cross-sectional diagnostic accuracy study evaluated MiniDock MTB in adolescents and adults with presumptive pulmonary tuberculosis across seven countries. Overall, MiniDock MTB showed strong performance with both sputum and tongue swabs, with sputum results closely approximating those of polymerase-chain-reaction assay and both sample types outperforming sputum-smear microscopy. Usability testing also suggested that the assay could be deployed with minimal training, and no adverse events related to the index test were reported. The generalizability of these findings is strengthened by the multicountry design, though interpretation is limited by the use under research settings, an imperfect microbiologic reference standard, and reduced precision in some subgroups, particularly those with lower bacillary burden. Nonetheless, this study suggests that molecular tuberculosis testing was reliable and could help expand testing access in decentralized settings, especially where nonsputum sampling is advantageous. 

Click to read the study in the NEJM (New England Journal of Medicine)

Relevant Reading: Diagnostic accuracy of swab-based molecular tests for tuberculosis using near-point-of-care platforms: a multi-country evaluation.

RELATED REPORTS

Poor baseline lung function associated with increased risk of incident tuberculosis

Routine confirmatory testing for primary aldosteronism may have low diagnostic value

In-Depth [cross-sectional study]: This cross-sectional diagnostic accuracy study enrolled 1380 participants 12 years of age or older with presumptive pulmonary tuberculosis at outpatient centers in India, Nigeria, the Philippines, South Africa, Uganda, Vietnam, and Zambia. Median age was 41 years, 43.7% of participants were female, 18.5% had human immunodeficiency virus infection, and 16.4% had culture-confirmed tuberculosis. MiniDock MTB was performed on both sputum swabs and tongue swabs and compared against a sputum liquid-culture microbiologic reference standard, sputum-smear microscopy, and polymerase-chain-reaction sputum Xpert MTB/RIF Ultra. With sputum swabs, MiniDock MTB had sensitivity of 85.7% and specificity of 97.6%. With tongue swabs, sensitivity was 79.6% and specificity was 99.5%. Sputum MiniDock MTB had sensitivity similar to sputum Xpert MTB/RIF Ultra (difference, -2.8 percentage points; 95% confidence interval [CI], -6.0 to 0.5), and greater sensitivity than sputum-smear microscopy (difference, 24.3 percentage points; 95% CI, 17.9 to 30.7). Tongue-swab MiniDock MTB also outperformed sputum-smear microscopy (difference, 18.3 percentage points; 95% CI, 12.0 to 24.7), though it remained less sensitive than sputum Xpert MTB/RIF Ultra. In a separate usability assessment, 18 health care workers in India and South Africa, none of whom had previously used the test, reported a median system usability score of 75, and 17 of 18 rated the test as acceptable. No adverse events related to MiniDock MTB were reported. Overall, these findings support MiniDock MTB as a feasible near-point-of-care molecular diagnostic option for pulmonary tuberculosis in high-burden settings.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc. 

Tags: diagnostic accuracysputumtuberculosis
Previous Post

Nirmatrelvir–ritonavir does not improve severe outcomes in adults vaccinated against COVID-19

Next Post

2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options

RelatedReports

Lung cancer collage: engraved lungs with the trachea and branching bronchi above a knitted wool scarf and a pine sprig
Chronic Disease

Poor baseline lung function associated with increased risk of incident tuberculosis

May 9, 2025
Surgical site anesthetic infusion may enhance analgesia after mastectomy
Endocrinology

Routine confirmatory testing for primary aldosteronism may have low diagnostic value

May 5, 2025
Chest imaging collage: engraved lungs with the windpipe and airways on a pale lightbox above a plain peak flow meter
2 Minute Medicine

Artificial intelligence demonstrates non-inferiority to radiologists at tuberculosis detection within a population with a high-disease burden

April 10, 2025
Quick Take: Discovery and validation of a prognostic proteomic signature for tuberculosis progression
Infectious Disease

Levofloxacin shows limited efficacy in preventing multidrug-resistant tuberculosis

March 5, 2025
Next Post
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options

Opioid prescribing collage: a calm man beside an amber pill bottle spilling white tablets onto a pill-counting tray

Rising amputation rates, especially among opioid-related hospitalizations

Migraine collage: a woman with her eyes closed and soft arcs radiating from her temple, a glass of water and a sleep mask

Calcitonin gene-related peptide therapies effective for chronic migraine

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Removing Race and Ethnicity From Dialysis Mortality Risk Adjustment Changes Facility Performance Rankings
  • AI Model Shows Promise in Predicting PTSD Risk Following Trauma
  • 2 Minute Medicine Rewind November 16, 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.